title: Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome.
authors.affiliation: Medizinische Klinik und Poliklinik I, University Hospital Dresden, Dresden, Germany, moritz.middeke@uniklinikum-dresden.de.
authors.forename: Jan Moritz
authors.initials: JM
authors.lastname: Middeke
authors.forename: Normi
authors.initials: N
authors.lastname: Bruck
authors.forename: Stefani
authors.initials: S
authors.lastname: Parmentier
authors.forename: Martin
authors.initials: M
authors.lastname: Bornhäuser
authors.forename: Johannes
authors.initials: J
authors.lastname: Schetelig
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002585:Cesarean Section; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D033461:Hyperuricemia / Q000209:etiology / Q000517:prevention & control; D050498:Live Birth; D049590:Postpartum Period; D054218:Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy / Q000503:physiopathology*; D011247:Pregnancy; D011252:Pregnancy Complications, Neoplastic / Q000503:physiopathology*; D011263:Pregnancy Trimester, Third; D011994:Recombinant Proteins / Q000627:therapeutic use; D012306:Risk; D015275:Tumor Lysis Syndrome / Q000453:epidemiology / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D014503:Urate Oxidase / Q000627:therapeutic use*; D014528:Uricosuric Agents / Q000627:therapeutic use*
chemical_list: D011994:Recombinant Proteins; D014528:Uricosuric Agents; C469709:rasburicase; D014503:Urate Oxidase